An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A Chinese biotech company called Ascletis said it has started a global Phase III clinical trial for a new pill called ASC30 that works like GLP-1 drugs, and it also reported encouraging early lab results for a different pill that combines three hormone actions (GLP-1, GIP, and amylin) in one fixed-dose oral treatment. In plain terms: they’re moving one experimental weight-loss/diabetes pill into late-stage testing in people, and they have promising preclinical (lab and animal) data on a more complex combo pill that would act on three targets at once. GLP-1 (glucagon-like peptide-1) is a naturally occurring gut hormone that helps control blood sugar and appetite. Existing drugs like semaglutide (branded as Ozempic and Wegovy) mimic GLP-1 and are usually injected. ASC30 is described as an oral small-molecule GLP-1 receptor agonist, which means it’s a pill designed to activate the same receptor as GLP-1 does, so it should lower blood sugar and reduce appetite without an injection. The combo drug adds activity on two other pathways: GIP (another gut hormone involved in insulin and metabolism) and amylin (a hormone that slows stomach emptying and reduces hunger). “Small molecule” here means the drug is a chemically made pill rather than a large protein or antibody. The announcement says Ascletis has moved ASC30 into a global Phase III trial, which is the big test before a company can ask regulators for approval. Phase III usually involves hundreds to thousands of people, but the release doesn’t give trial size or timelines. The news also mentions “positive preclinical data” for the triple-action pill, which means the findings came from lab experiments and likely animal studies, not humans. Preclinical success is an important step, but it doesn’t guarantee the same effects or safety in people. The company didn’t publish detailed results in this snippet, so we don’t know how big the effects were or what side effects showed up in those early tests. Why this matters is practical: oral pills that mimic GLP-1 (and combo pills that target multiple appetite and metabolism pathways) could make effective diabetes and weight-loss treatments easier to use than injections. That could broaden access and convenience for people who need these medications. If the Phase III trial for ASC30 succeeds, it might offer a pill alternative to injectable drugs like Ozempic or Wegovy. The triple combo, if it eventually works in humans, could offer stronger or more durable benefits by hitting three hormone systems at once. Caveats are important. Phase III is a big, expensive step and many drugs fail at this stage due to lack of effectiveness or safety problems. “Preclinical” means the combo drug’s data so far are from non-human studies, and human responses can be different. Side effects common to GLP-1 drugs include nausea, vomiting, and gastrointestinal issues; adding GIP and amylin effects could change the side-effect picture. The company’s announcement doesn’t replace peer-reviewed data or regulatory review. Until clinical trials in people are complete and published, we can’t know how well these pills will work or how safe they are. Bottom line: Ascletis has started late-stage testing of an oral GLP-1 pill and has encouraging early lab results for a triple-action oral candidate, but real proof of benefit and safety will depend on upcoming human trial results.
Source: PR Newswire